ライフサイエンスコーパス: event-free survival

1 The main outcome of interest was event-free survival.

2 s, CABG affords better major adverse cardiac event-free survival.

3 ed with increased toxicity without improving event-free survival.

4 vHD; overall survival; and chronic-GvHD-free event-free survival.

5 .005 and .02) were associated with a shorter event-free survival.

6 The primary endpoint for this study was event-free survival.

7 c graft-versus-host disease had no effect on event-free survival.

8 te, more frequent reinduction, and decreased event-free survival.

9 Our primary endpoint was event-free survival.

10 oved pathological complete response rate and event-free survival.

11 er, with higher ejection fraction and better event-free survival.

12 n/kg as independent prognostic indicators of event-free survival.

13 gnostic Index (IPI) for overall survival and event-free survival.

14 agnosis of which were highly associated with event-free survival.

15 iations with disease progression and reduced event-free survival.

16 (P=0.036) were independently associated with event-free survival.

17 f the bundled-payment program on overall and event-free survival.

18 2 positive had significantly worse five-year event-free-survival (33% vs 64%, p = 0.03 and 14% vs 59%

19 tuximab shows improvement of outcome (median event-free survival, 51 vs 83 months).

20 s needing scar dechanneling alone had better event-free survival (80% versus 62%) and lower mortality

21 There were no significant differences in event-free survival (90.0% +/- 4.7% [SE] v.

22 BI patients achieved significantly prolonged event-free survival (90.1% [95% confidence interval, 88.

23 ed overall survival and subgroup analyses of event-free survival according to disease duration at scr

24 evascularization had a significant effect on event-free survival (adjusted hazard ratio, 0.25; P<0.00

25 We aimed to assess event-free survival after high-dose chemotherapy with bu

26 s (interquartile range: 7-16 months), median event-free survival after IRE was 8 months (95% confiden

27 Five-year event-free survival after SLN alone was 93% with no isol

28 Cumulative event-free survival after surgery was 72% at 40 years.

29 otherapy significantly prolonged overall and event-free survival among patients with AML and a FLT3 m

30 The primary endpoint was 3-year event-free survival, analysed by intention to treat.

31 th inferior transformation-free survival and event-free survival and an independent predictor of infe

32 ed risk stratification trees based on 5 year event-free survival and clinical applicability.

33 ty as an independent prognostic indicator of event-free survival and maintenance of Child-Pugh class

34 Event-free survival and overall survival (OS) hazard rat

35 Event-free survival and overall survival (OS) rates at 2

36 With a median follow-up of 4.8 years, 5-year event-free survival and overall survival (OS) rates were

37 OCTN1 (SLC22A4; ETT) strongly predicts poor event-free survival and overall survival in multiple coh

38 The 5-year event-free survival and overall survival rates+/-SE were

39 At 59 months median follow-up, the event-free survival and overall survival were 62% and 74

40 The 5-year event-free survival and overall survival were 91.4% (95%

41 Event-free survival and overall survival were determined

42 diagnosis <2 years) results in satisfactory event-free survival and overall survival, and to correla

43 ter chemotherapy) and their association with event-free survival and overall survival.

44 on to offer prognostic significance for both event-free survival and overall survival.

45 The primary outcomes were event-free survival and overall survival.

46 aim was to establish the association between event-free survival and patients' minimal residual disea

47 We aimed to identify predictors of event-free survival and survival with acceptable hrQoL (

48 Clinical efficacy assessments included event free survival, and change from baseline of two ass

49 All 24 (100%) patients met 12-month event-free survival, and nine had sufficient follow-up d

50 ted with the International Prognostic Index, event-free survival, and number of circulating Tregs.

51 ed to investigate time to local progression, event-free survival, and OS.

52 icacy in terms of time to local progression, event-free survival, and overall survival (OS).

53 response rate, similar transplantation rate, event-free survival, and overall survival, less toxicity

54 cluding primary refractoriness and relapse), event-free survival, and overall survival.

55 The 2-year Kaplan-Meier ocular survival, event-free survival, and progression-free survival estim

56 y efficacy end point of the study was 3-year event-free survival, and results were analyzed on an int

57 , duration of response, progression-free and event-free survivals, and safety.

58 chemotherapy with or without rituximab, with event-free survival as the primary end point.

59 emission with incomplete recovery), inferior event-free survival as well as overall survival in both

60 rvival, progression-free survival (PFS), and event-free survival at 10 years were (+/- SE) 96.3% +/-

61 ed an overall response, a complete response, event-free survival at 12 months and 24 months from enro

62 The primary end point was event-free survival at 2 years (2-year EFS).

63 how that the difference between the rates of event-free survival at 2 years in the two groups was not

64 Event-free survival at 2 years was 77.0% (95% CI 72.1-82

65 The primary endpoint was non-inferiority of event-free survival at 2 years, analysed by intention to

66 Overall and event-free survival at 3 years were 83.9% and 80.4%, res

67 Starting from randomization, the rate of event-free survival at 4 years was 79% (95% confidence i

68 Event-free survival based on interim PET/CT (RIW) respon

69 ever, HCST conferred a significant long-term event-free survival benefit.

70 ian follow-up of 5.4 years (IQR 3.1-6.8) the event-free-survival benefit from the addition of trastuz

71 group; the unadjusted hazard ratio (HR) for event-free survival between the two randomised HER2-posi

72 and 23 with chemotherapy alone), the HR for event-free survival between those with and without trast

73 70.0 ng/mmol) was associated with 88% 5-year event-free survival compared with 50% with high urinary

74 gnificantly worse overall survival (OS), and event-free survival compared with B-other with a 5-year

75 42, 0.20-0.89, p=0.024) predicted for better event-free survival compared with imatinib 400 mg, but t

76 ents with Ph-like ALL had an inferior 5-year event-free survival compared with patients with non-Ph-l

77 ts is associated with significantly inferior event-free survival compared with stage III non-MLBL DLB

78 on day 46 seemed to have an inferior 10-year event-free survival compared with the 126 with negative

79 After a median follow-up of 40.6 months, the event-free survival, cumulative incidence of relapse, an

80 o-group and in one patient in the Epi-group (event-free survival curves by Grey-test, P=0.03).

81 patients, Kaplan-Meier major adverse cardiac event-free survival curves demonstrated a significant be

82 One-year Kaplan-Meier estimates of adverse event-free survival (death, heart failure hospitalizatio

83 ars earlier (p = 0.002) and had worse 4-year event-free survival (death, myocardial infarction, strok

84 The primary end point of HALT-MS is event-free survival defined as survival without death or

85 The primary endpoint was event-free survival, defined as being alive without graf

86 The primary end point was event-free survival, defined as time from randomization

87 Event-free survival did not differ between the lapatinib

88 Event-free survival did not differ between treatment gro

89 alysis, patients with preeclampsia had worse event-free survival during 1-year follow-up (P=0.047).

90 At 2 years, event free survival (EFS) and overall survival (OS) were

91 n non-DS patients, resulting in lower 8-year event-free survival (EFS) (64% +/- 2% vs 81% +/- 2%, P <

92 genetic profile and a significantly improved event-free survival (EFS) (94%) compared with patients w

93 The primary objective was 1-year event-free survival (EFS) after HLA allele-matched (at H

94 Survivor functions for event-free survival (EFS) and OS were estimated using th

95 e remission) was the primary end point, with event-free survival (EFS) and overall survival (OS) as s

96 BM at diagnosis strongly predicted for worse event-free survival (EFS) and overall survival (OS) in a

97 adding GO to standard chemotherapy improved event-free survival (EFS) and overall survival (OS) in c

98 ated the hazard ratios (HRs) and 95% CIs for event-free survival (EFS) and overall survival (OS) usin

99 s old; median follow-up, 5.38 years), 5-year event-free survival (EFS) and overall survival (OS) were

100 cology Group study AREN0534 aimed to improve event-free survival (EFS) and overall survival (OS) whil

101 avorable-histology Wilms tumors (FHWTs) with event-free survival (EFS) and overall survival (OS) with

102 To quantify the relationships between event-free survival (EFS) and overall survival (OS) with

103 Four-year event-free survival (EFS) and overall survival estimates

104 studies regarding the influence of weight on event-free survival (EFS) and treatment-related toxicity

105 We have previously shown that event-free survival (EFS) at 24 months (EFS24) is a clin

106 Overall survival and event-free survival (EFS) at 5 years were 74% and 63%, r

107 Purpose To investigate whether event-free survival (EFS) can be maintained among childr

108 howed that the cumulative proportions of 3-y event-free survival (EFS) for 3-mo BCR-ABL levels was 95

109 The median event-free survival (EFS) for the entire study populatio

110 The primary objective of the trial was event-free survival (EFS) from randomization.

111 the risk for relapse and the probability of event-free survival (EFS) in children with acute lymphob

112 Obesity is associated with poorer event-free survival (EFS) in pediatric acute lymphoblast

113 ad morphologic induction failure with 5-year event-free survival (EFS) of 50.7% (95% CI, 37.4 to 64.0

114 A total of 312 HR patients had a 5-year event-free survival (EFS) of 58.9% (standard error [SE]

115 an 8 ng/mL treated with rituximab had 3-year event-free survival (EFS) of 59% and 79% and 3-year over

116 ssigned to Capizzi methotrexate had a 5-year event-free survival (EFS) of 82% versus 75.4% (P = .006)

117 s with end-induction MRD <0.01% had a 5-year event-free survival (EFS) of 87% +/- 1% vs 74% +/- 4% fo

118 DNA index (DI) (490 patients), had a 6-year event-free survival (EFS) of 89.0% (standard error [SE]

119 h embryonal RMS, have an estimated long-term event-free survival (EFS) of less than 20%.

120 tic Index risk factors and age (> 70 years), event-free survival (EFS) of patients with bulky disease

121 We sought to determine the effect on event-free survival (EFS) of staging variables, extent o

122 MRD-based standard-risk patients, the 5-year event-free survival (EFS) rate was 93% (SE 2%), the 5-ye

123 Overall survival (OS) and event-free survival (EFS) rates at 10 years were, respec

124 9% for TRIL and 41% for DL (P = .78); 4 year event-free survival (EFS) was 27% for TRIL and 27% for D

125 ear overall survival (OS) was 58% and 6-year event-free survival (EFS) was 38%.

126 oor-prognosis patients (IPI, 3 to 5); 3-year event-free survival (EFS) was 71%, 75%, and 67%, respect

127 Five-year event-free survival (EFS) was 75.0% in patients with 1q

128 relapses at a median of 11.5 months; 5-year event-free survival (EFS) was 77% (range, 62% to 87%).

129 Among 1,712 eligible patients, 4-year event-free survival (EFS) was 85.0%: 86.9% for RERs and

130 r overall survival was 95.5%, and the 5-year event-free survival (EFS) was 89.8%.

131 The 3-year overall survival was 94%, and event-free survival (EFS) was 91%.

132 a median follow-up of 62 months, the 5-year event-free survival (EFS) was significantly better for t

133 Three-year overall survival and event-free survival (EFS) were 95% and 82%, respectively

134 n and ocular survival, patient survival, and event-free survival (EFS) were calculated and then compa

135 ic factors, early metabolic change, pCR, and event-free survival (EFS) were examined (log-rank test).

136 evaluated in relation to cancer occurrence, event-free survival (EFS), and overall survival (OS).

137 ical benefit, such as disease-free survival, event-free survival (EFS), and overall survival (OS).

138 Overall survival (OS), event-free survival (EFS), and progression-free survival

139 with decreased 3-year overall survival (OS), event-free survival (EFS), and relapse risk from the end

140 emia of Down syndrome (ML-DS) have favorable event-free survival (EFS), but experience significant tr

141 Secondary end points included 5-year event-free survival (EFS), distant disease-free survival

142 ween the preimatinib and imatinib cohorts in event-free survival (EFS), OS, and relapse-free survival

143 Treatment outcomes included event-free survival (EFS), overall survival (OS), and cu

144 loid leukemia (AML) is associated with worse event-free survival (EFS), overall survival (OS), and cu

145 Five-year event-free survival (EFS), overall survival (OS), and lo

146 primary endpoints were overall survival and event-free survival (EFS), probabilities of overall surv

147 Ph(-) had worse failure-free survival (FFS), event-free survival (EFS), transformation-free survival

148 Primary end points were event-free survival (EFS), treatment discontinuation, no

149 The primary outcome was event-free survival (EFS), which was defined as time to

150 vant therapy, and reports of both pCR and an event-free survival (EFS)-type outcome.

151 Other outcomes of interest included event-free survival (EFS).

152 ethnicity-were evaluated for their impact on event-free survival (EFS).

153 ues (SUVmax) and total lesion glycolysis, on event-free survival (EFS).

154 ls defined using RNA sequencing with pCR and event-free survival (EFS).

155 CS of more than 2 being associated with poor event-free survival (EFS).

156 The main end point was event-free survival (EFS).

157 The primary end point was event-free survival (EFS).

158 ated with chemotherapy/surgery alone [5-year event-free survival (EFS): 85.7%].

159 rall survival (OS, 46% vs 28%; P < .001) and event-free survival (EFS, 36% vs 21%; P < .001) at 5 yea

160 Event-free survival (EFS, primary endpoint) and other cl

161 ing the greatest prognostic significance for event-free survival (EFS, the main endpoint of the IELSG

162 vage therapy (37% vs 26%; P = .07) and lower event-free survival (EFS; 4-year EFS, 31% vs 43%; P < .0

163 (89% +/- 3% vs 90% +/- 4%; Plog-rank = .64), event-free survival (EFS; 87% +/- 3% vs 89% +/- 4%; Plog

164 ethasone was associated with superior 5-year event-free survival (EFS; 90% v 81% for prednisone; P =

165 e level of MRD was inversely correlated with event-free survival (EFS; P < .004) and positively corre

166 e extent of first operation had no impact on event-free survival (EFS; P = .207), local progression-f

167 dverse overall survival (OS; P = 0.0441) and event-free survival (EFS; P = 0.0114) compared with low

168 Outcome measures were event-free survival (EFS; primary) and overall survival

169 correlated with immune cell infiltration and event-free-survival (EFS).

170 vs 75% +/- 3% [idarubicin], Plogrank = .65; event-free survival [EFS] 59% +/- 3% vs 53% +/- 3%, Plog

171 pse risk [RR]: GO 36% v No-GO 34%, P = .731; event-free survival [EFS]: GO 53% v No-GO 58%, P = .456)

172 Kaplan-Meier (event-free) survival estimates were used for the endpoin

173 ach associated with an increased risk for an event-free survival event ( P = .48, P = .08, P = .065,

174 307 event-free survival events were reported (153 in the MAP

175 educed for patients achieving post-treatment event-free survival for 24 months (pEFS24; standardized

176 Three-year event-free survival for all patients (N = 229) was 44% a

177 a QLV ratio </=0.70 had significantly worse event-free survival for all study end points--hazard rat

178 SPIO enhancement was associated with reduced event-free survival for aneurysm rupture or repair (P=0.

179 The groups differed significantly in event-free survival for incident ESRD and composite outc

180 The 5-year event-free survival for these 20 children was worse than

181 Those with multiple variants had worse event-free survival from all-cause death, cardiac transp

182 x and phenotype, we retrospectively assessed event-free survival from birth to the first clinical vis

183 d a less severe clinical course with greater event-free survival from major cardiac events (P=0.04) c

184 These results show a sustained benefit in event-free survival from trastuzumab-containing neoadjuv

185 re SCD, with expected HSCT survival >95% and event-free survival >85%.

186 or International Prognostic Index factors in event-free survival (hazard ratio [HR] of ABC-like disea

187 for death, 0.78; one-sided P=0.009), as was event-free survival (hazard ratio for event or death, 0.

188 strategy had a significantly more favorable event-free survival (hazard ratio, 0.48; 95% confidence

189 nt adverse prognostic marker for hematologic event-free survival (hazard ratio, 2.94; 95% CI, 1.37 to

190 2), translating into a prolonged hematologic event-free survival (hemEFS; median, 46.1 vs 28.1 months

191 2.19, 95% CI 1.25-3.85) and reduced cardiac event-free survival (HR 2.27, 95% CI 1.31-3.94).

192 fect against RB invasion, as demonstrated by event-free survival (HR = 0.53, P = 0.007 for GC versus

193 f 53 months, no differences were detected in event-free survival (HR, 0.99; stratified log-rank P = .

194 ence interval [CI], 1.05-1.87; P < .021) and event-free survival (HR, 1.39; 95% CI, 1.05-1.82; P < .0

195 apse-free survival (HR, 2.28; P = .002), and event-free survival (HR, 1.79; P = .009).

196 th rituximab remained associated with longer event-free survival in a multivariate analysis.

197 Using the lncRNAs most associated with event-free survival in a training cohort of 148 older pa

198 The primary endpoint was 2 year event-free survival in all registered eligible patients

199 x of these genes is associated with inferior event-free survival in both patient cohorts.

200 We sought to analyze long-term chimerism and event-free survival in children undergoing transplantati

201 ERPRETATION: Busulfan and melphalan improved event-free survival in children with high-risk neuroblas

202 t of combination cardioprotective therapy on event-free survival in Duchenne muscular dystrophy.

203 p between preoperative exercise capacity and event-free survival in hepatocellular carcinoma (HCC) pa

204 Event-free survival in nonobstructive CAD with high CT-L

205 chemotherapy (>/=10% viable tumour) improved event-free survival in patients with high-grade osteosar

206 with haemopoietic stem-cell rescue improves event-free survival in patients with high-risk neuroblas

207 Five-year event-free survival in patients with SETBP1 mutations wa

208 after therapy with a histologic response and event-free survival in pediatric and young adult patient

209 rs1801131 (hazard ratio 3.1; P = .015) with event-free survival in the ALL-BFM 2000 study population

210 Event-free survival in this group was significantly lowe

211 Event-free survival is also reduced in patients with cor

212 t vs absent: HR, 0.18; P = .006), and better event-free survival (KIR2DS1 present vs absent: HR, 0.31

213 MOLLI-ECV >/= the median (28.9%) had shorter event-free survival (log-rank, P=0.028).

214 The primary outcome measure was event-free survival measured in the intention-to-treat p

215 ce, was associated with inferior hematologic event-free survival (median, 3.4 v 8.8 months, respectiv

216 cal outcomes included overall survival (OS), event-free-survival, nonrelapse mortality (NRM), and gra

217 a median follow-up of 17.1 months and median event-free survival of 17.8 months.

218 n = 92, P < .0001) and 4-year probability of event-free survival of 33 +/- 6% vs 62 +/- 5% (P = .0013

219 ome in the matched HFpEF cohort, with 1-year event-free survival of 62% (95% CI, 60%-64%) versus 65%

220 ated for standard-risk ALL and had a 10-year event-free survival of 88.9% (43.3-98.4).

221 with an AV-Vel between 3 and 3.9 m/s had an event-free survival of 94 +/- 4%, 88 +/- 6%, 65 +/- 9%,

222 This study sought to determine cardiac event-free survival of a consecutive cohort with suspect

223 With improved event-free survival of patients undergoing primary biopr

224 Although event-free survival or overall survival did not differ b

225 Secondary end points were event-free survival, overall survival, and safety.

226 elated donors, no significant differences in event-free survival, overall survival, or nonrelapse mor

227 gnificantly correlated with poor overall and event-free survival (P < 0.05).

228 All patients showed a 3-year probability of event-free survival (pEFS) of 55%.

229 ance therapy after transplantation prolonged event-free survival, progression-free survival, and over

230 er B-cell [GCB]-like DLBCL) were observed in event-free survival, progression-free survival, and over

231 ninferiority was set at -8.5% for the 3-year event-free survival rate (EFS), equivalent to 1.43 in te

232 The primary outcome was one-year event-free survival rate for the combined end point of d

233 f 4.6 years, there was a significantly lower event-free survival rate in patients with ASP progressio

234 atients remained relapse free, with a 2-year event-free survival rate of 50% +/- 8%.

235 e current standard of care and results in an event-free survival rate of 50% to 60%, indicating that

236 tained remission was achieved with a 6-month event-free survival rate of 67% (95% confidence interval

237 , over a median of 3 years of follow-up, the event-free survival rate was 100%, and no patients recei

238 2-year event-free survival rate was 81% (95% CI 64-90).

239 During a median of 5 years of follow-up, the event-free survival rate was 93%, and the overall surviv

240 hod was used to calculate 5-year overall and event-free survival rates by cancer stage, and the Cox p

241 The 5-year event-free survival rates for patients with stages 0 to

242 t VB stroke (P = .04), with 12- and 24-month event-free survival rates of 78% and 70%, respectively,

243 5% vs 0.9%, P = .00013), resulting in 5-year event-free survival rates of 83.9 +/- 0.9% for dexametha

244 0.45 to 0.98; P=0.04); the estimated 2-year event-free survival rates were 65% (95% CI, 56 to 75) an

245 The 1- and 2-year cumulative event-free survival rates were 87% and 81%.

246 Factors associated with event-free survival, relapse-free survival, and incidenc

247 5-year event free survival significantly differed between the i

248 nonobstructive CAD and high CT-LeSc had hard event-free survival similar to patients with obstructive

249 Four-year event-free survival (+/- standard deviation [SD]) did no

250 powerful predictor of major adverse cardiac event-free survival than choice of therapy (hazard ratio

251 sociated with a better biomarker profile and event-free survival than HF-REF and HF-PEF.

252 BG led to lower rates of 5-year survival and event-free survival than on-pump CABG.

253 th blinatumomab resulted in a higher rate of event-free survival than that with chemotherapy (6-month

254 The primary end point was 2-year event-free survival; the planned accrual was 38 patients

255 We evaluated the risk of relapse at event-free survival time points in cHL and compared the

256 ersmith Infant Neurological Examination) and event-free survival (time to death or the use of permane

257 Overall survival (OS), event-free survival, transplant-related mortality (TRM),

258 40% (6/15 of evaluable patients) and median event-free survival was 17 months.

259 n follow-up of 20 months, the overall median event-free survival was 18 months: 20 and 13 months for

260 r disease-free survival was 31.2% and 16.2%, event-free survival was 21.5% and 12.9%, and overall sur

261 Cumulative event-free survival was 25% after 40 years.

262 de, and melphalan group had an event; 3-year event-free survival was 50% (95% CI 45-56) versus 38% (3

263 5 year event-free survival was 58% (95% CI 48-66) in patients i

264 er a median follow-up of 5 years, the 3-year event-free survival was 62% versus 65% ( P = .83).

265 In patients with T-LL, 3-year event-free survival was 63.3% (95% CI, 54.2% to 71.0%),

266 edian 58 months' potential follow-up, 3-year event-free survival was 69% and 3-year overall survival

267 e incidence of EBRT was 5.9% (SE +/- 3), and event-free survival was 69.2% (SE +/- 27.2).

268 Estimated 2-year event-free survival was 69.7% (95% CI 66.2-73.0).

269 37 months (IQR 30-44), the estimated 2 year event-free survival was 75% (95% CI 63-84).

270 Cumulative event-free survival was 76.8% with a high CT-LeSc and 96

271 low-up of 3.77 years (IQR 3.50-4.22), 3-year event-free survival was 78% (95% CI 70-84) in the lapati

272 Overall event-free survival was 78.4% (90% CI, 60.1%-89.0%) at 3

273 months), the overall survival was 91.4%, and event-free survival was 81.4%.

274 At 5 years, event-free survival was 84% +/- 4% (SE) and overall surv

275 Estimated 4-year event-free survival was 89.7% (95% confidence interval 8

276 2 year event-free survival was 92.6% (95% CI 89.6-95.7) for tre

277 Event-free survival was 99.0% at 1 year, 96.2% at 5 year

278 n follow-up of 70 months (IQR 52-91), 5-year event-free survival was better in the augmented treatmen

279 Event-free survival was defined as avoidance of external

280 Although the bleeding event-free survival was different in VWD types, only a B

281 Two-year event-free survival was estimated at 49.0% (95% confiden

282 Kaplan-Meier event-free survival was evaluated in 4 patient subgroups

283 1%] vs. 0 of 37 [0%]), and the likelihood of event-free survival was higher in the nusinersen group t

284 After a median follow-up of 30 months, event-free survival was longer in the rituximab group th

285 Event-free survival was lower with increasing age at tra

286 Long-term post-PMV event-free survival was predicted by age, degree of mitr

287 sthoc analyses suggested that cardiovascular event-free survival was significantly better in the high

288 Landmark analyses showed that 3-year event-free survival was significantly improved for women

289 Median event-free survival was significantly prolonged by LDAC

290 the provisional risk classification, 10-year event-free survival was significantly worse for patients

291 By Kaplan-Meier analysis, event-free survival was significantly worse in patients

292 Event-free survival was strongly associated with patholo

293 Major cardiovascular adverse events-free survival was worse in patients with MVO (P=0

294 Early safety at 30 days (ie, event-free survival) was 84%.

295 deled with treatment x time interaction) for event-free survival were 0.35 (95% CI, 0.16-0.74) at 2 y

296 MSDs; however, estimated 5-year overall and event-free survival were worse for URD recipients (71% a

297 nfiltrating lymphocytes (TILs) and five-year-event-free-survival were examined.

298 The primary end point was event-free survival (with an event defined as disease pr

299 The 5-year event-free survival (with standard error) did not differ

300 ters differ significantly in terms of 4-year event-free survival, with the lowest methylation cluster